The patient with inflammatory residual risk: Who is it?Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany
Prof. Wolfgang Koenig explains the role of inflammation in the atherogenic process and how to identify patients with residual inflammatory risk.
Video navigation menu
- Residual risk still exists after appropriate treatment of risk factors 01:00
- The concept of residual inflammatory risk 03:47
- The impact of baseline IL-6 / hsCRP on outcome (STABILITY trial) 05:18
- CRP as sensitive marker of the inflammation cascade 07:08
- Case history: the role of inflammation to identify patients at increased CV risk 09:30
- "The lower the better" - not only for LDL, but also for CRP 12:44
This educational video is part of a series of Inflammation videos that are aimed to provide guidance and perspectives on the implications of addressing inflammation in CVD. These expert views may help translate scientific findings to future clinical practice, by improving personalized CV risk management.
This recording was developed under auspices of PACE-cme.
The views expressed in this recording are those of the presenter and do not necessarily reflect the views of PACE-cme.
Wolfgang Koenig, MD, PhD, FRCP, FACC, FAHA, FESC is a Professor of Medicine/Cardiology at the Deutsches Herzzentrum München, Technische Universität München and an established investigator of the Munich Heart Alliance within the DZHK (German Centre for Cardiovascular Research) and head of the Cardiometabolics Unit.
Funding to produce this educational video was provided by an unrestricted educational grant from Novartis.